JBC Anatrace, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M314116200 on February 2, 2004

J. Biol. Chem., Vol. 279, Issue 16, 15938-15945, April 16, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/16/15938    most recent
M314116200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, G.
Right arrow Articles by Kuret, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, G.
Right arrow Articles by Kuret, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Casein Kinase 1 Delta Phosphorylates Tau and Disrupts Its Binding to Microtubules*

Guibin Li{ddagger}, Haishan Yin§, and Jeff Kuret{ddagger}§¶||

From the {ddagger}Center for Molecular Neurobiology, §Ohio State Biochemistry Program, and the Department of Molecular and Cellular Biochemistry, Ohio State University College of Medicine and Public Health, Columbus, Ohio 43210

Tau hyperphosphorylation precedes neuritic lesion formation in Alzheimer's disease, suggesting it participates in the tau fibrillization reaction pathway. Candidate tau protein kinases include members of the casein kinase 1 (CK1) family of phosphotransferases, which are highly overexpressed in Alzheimer's disease brain and colocalize with neuritic and granulovacuolar lesions. Here we characterized the contribution of one CK1 isoform, Cki{delta}, to the phosphorylation of tau at residues Ser202/Thr205 and Ser396/Ser404 in human embryonic kidney 293 cells using immunodetection and fluorescence microscopy. Treatment of cells with membrane permeable CK1 inhibitor 3-[(2,3,6-trimethoxyphenyl)methylidenyl]-indolin-2-one (IC261) lowered occupancy of Ser396/Ser404 phosphorylation sites by >70% at saturation, suggesting that endogenous CK1 was the major source of basal phosphorylation activity at these sites. Overexpression of Cki{delta} increased CK1 enzyme activity and further raised tau phosphorylation at residues Ser202/Thr205 and Ser396/Ser404 in situ. Inhibitor IC261 reversed tau hyperphosphorylation induced by Cki{delta} overexpression. Co-immunoprecipitation assays showed direct association of tau and Cki{delta} in situ, consistent with tau being a Cki{delta} substrate. Cki{delta} overexpression also produced a decrease in the fraction of bulk tau bound to detergent-insoluble microtubules. These results suggest that Cki{delta} phosphorylates tau at sites that modulate tau/microtubule binding, and that the expression pattern of Cki{delta} in Alzheimer's disease is consistent with it playing an important role in tau aggregation.


Received for publication, December 23, 2003 , and in revised form, January 26, 2004.

* This work was supported by National Institutes of Health Grant AG14452 (to J. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Center for Neurobiotechnology, 1060 Carmack Rd., Columbus, OH 43210. Tel.: 614-688-5899; Fax: 614-292-5379; E-mail: kuret.3{at}osu.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
D. P. Hanger, H. L. Byers, S. Wray, K.-Y. Leung, M. J. Saxton, A. Seereeram, C. H. Reynolds, M. A. Ward, and B. H. Anderton
Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis
J. Biol. Chem., August 10, 2007; 282(32): 23645 - 23654.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Bandyopadhyay, G. Li, H. Yin, and J. Kuret
Tau Aggregation and Toxicity in a Cell Culture Model of Tauopathy
J. Biol. Chem., June 1, 2007; 282(22): 16454 - 16464.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Ding, T. A. Matthews, and G. V. W. Johnson
Site-specific Phosphorylation and Caspase Cleavage Differentially Impact Tau-Microtubule Interactions and Tau Aggregation
J. Biol. Chem., July 14, 2006; 281(28): 19107 - 19114.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Necula and J. Kuret
Pseudophosphorylation and Glycation of Tau Protein Enhance but Do Not Trigger Fibrillization in Vitro
J. Biol. Chem., November 26, 2004; 279(48): 49694 - 49703.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.